The anti-inflammatory potential of an oral p38 MAPK inhibitor in humans in vivo suggests that p38 MAPK inhibitors may provide a new therapeutic option in the treatment of inflammatory diseases. Boehringer Ingelheim. 2002 Branger J, et al
Dr. Noboru Ashida, Department of Geriatric Medicine, Graduate School of Medicine, Kyoto University, 54 Kawaramachi, Shogoin Sakyo-ku, Kyoto 606-8507, Japan. Voice +81-75-751-3465; fax: +81-75-751-3574; ash@kuhp.kyoto.u.ac.jp.
HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY. Judith Branger, Bernt van den Blink, Sebastiaan Weijer, Abhya Gupta, Sander J.H. van Deventer, C. Erik Hack, Maikel P. Peppelenbosch, and Tom van der Poll
Mitogen-activated protein kinase p38 is a serin/threonine kinase originally isolated from lipopolysaccharide stimulated monocytes. There are 4 isoforms; p38-a activation has been most widely studied for inflammation...